BioSpace News Archive

Palatin Technologies, Inc. today announced it has initiated a clinical development program evaluating bremelanotide, a melanocortin receptor 4 (MCR4) agonist, co-formulated with a PDE5 inhibitor (PDE5i), for the treatment of erectile dysfunction (ED) in patients that do not respond to PDE5i monotherapy.

Femasys Inc. announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Innate Pharma SA announced that members of its senior management team are scheduled to participate in the following upcoming conference.

Affimed N.V. reported financial results and provided an update on clinical and corporate progress for the second quarter of 2023.

Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, highlighted pipeline progress and reported second quarter 2023 financial results.

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30, 2023, and provided a clinical and corporate update.

Vaxxinity, Inc. announced the print publication of Phase 2a clinical trial data in The Lancet’s eBioMedicine, stating that UB-311 “was safe and well-tolerated,” with early clinical data demonstrating a trend for slowing cognitive decline in mild Alzheimer’s disease.

CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the second quarter ended June 30, 2023.

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2023.

BIOLASE, Inc., the global leader in dental lasers, announced its financial results for the second quarter ended June 30, 2023.